Antony Loebel

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint Improvement in prosocial functioning after a switch to ziprasidone treatment
    Antony Loebel
    Pfizer, Inc, New York, NY 10016, USA
    CNS Spectr 9:357-64. 2004
  2. ncbi request reprint Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine
    Philip D Harvey
    Department of Psychiatry, Box 1229 Mount Sinai School of Medicine, New York, NY 10029, USA
    J Neuropsychiatry Clin Neurosci 18:54-63. 2006
  3. doi request reprint Weight effects associated with antipsychotics: a comprehensive database analysis
    Bruce Parsons
    Pfizer Inc, 235 E 42nd Street, New York, NY 10017 5755, USA
    Schizophr Res 110:103-10. 2009
  4. doi request reprint Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Int Clin Psychopharmacol 27:165-76. 2012
  5. ncbi request reprint The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Psychopharmacology (Berl) 187:356-63. 2006
  6. ncbi request reprint Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
    Philip D Harvey
    Mt Sinai School of Medicine, New York University, 1425 Madison Avenue, Fourth Floor, New York, NY 10029, USA
    Schizophr Res 66:101-13. 2004
  7. ncbi request reprint Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder
    Lewis Warrington
    Pfizer Inc, New York, New York 10017, USA
    CNS Drugs 21:835-49. 2007
  8. ncbi request reprint Electrocardiographic changes with ziprasidone
    Antony Loebel
    J Am Acad Child Adolesc Psychiatry 45:636-7; author reply 638-9. 2006
  9. ncbi request reprint Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study
    Dan Zimbroff
    Pacific Clinical Research, West Covina, California, USA
    Int Clin Psychopharmacol 22:363-70. 2007
  10. doi request reprint Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008

Detail Information

Publications13

  1. ncbi request reprint Improvement in prosocial functioning after a switch to ziprasidone treatment
    Antony Loebel
    Pfizer, Inc, New York, NY 10016, USA
    CNS Spectr 9:357-64. 2004
    ....
  2. ncbi request reprint Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine
    Philip D Harvey
    Department of Psychiatry, Box 1229 Mount Sinai School of Medicine, New York, NY 10029, USA
    J Neuropsychiatry Clin Neurosci 18:54-63. 2006
    ....
  3. doi request reprint Weight effects associated with antipsychotics: a comprehensive database analysis
    Bruce Parsons
    Pfizer Inc, 235 E 42nd Street, New York, NY 10017 5755, USA
    Schizophr Res 110:103-10. 2009
    ....
  4. doi request reprint Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study
    Leslie Citrome
    Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, New York, USA
    Int Clin Psychopharmacol 27:165-76. 2012
    ..All-cause discontinuation rates were higher for lurasidone versus risperidone. Long-term treatment with lurasidone was generally well tolerated in this study, with minimal effects on weight and metabolic outcomes...
  5. ncbi request reprint The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Psychopharmacology (Berl) 187:356-63. 2006
    ..Thus, this study used a database from an existing clinical trial and examined the relationships between changes in clinical symptoms and cognitive deficits with several different strategies...
  6. ncbi request reprint Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
    Philip D Harvey
    Mt Sinai School of Medicine, New York University, 1425 Madison Avenue, Fourth Floor, New York, NY 10029, USA
    Schizophr Res 66:101-13. 2004
    ....
  7. ncbi request reprint Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder
    Lewis Warrington
    Pfizer Inc, New York, New York 10017, USA
    CNS Drugs 21:835-49. 2007
    ..The favourable tolerability of ziprasidone has been confirmed in long-term extension studies and its use was not associated with weight gain or dyslipidaemia. Ziprasidone-related movement disorders occurred infrequently...
  8. ncbi request reprint Electrocardiographic changes with ziprasidone
    Antony Loebel
    J Am Acad Child Adolesc Psychiatry 45:636-7; author reply 638-9. 2006
  9. ncbi request reprint Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study
    Dan Zimbroff
    Pacific Clinical Research, West Covina, California, USA
    Int Clin Psychopharmacol 22:363-70. 2007
    ..Differences between the two drugs in the onset of therapeutic effect warrant further investigation...
  10. doi request reprint Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders
    Ofer Agid
    Center for Addiction and Mental Health, 250 College St, Toronto, Ontario, Canada M5T 1R8
    Schizophr Res 102:241-8. 2008
    ..The objective of this study was to evaluate the early response (within the first 24 h) in psychosis with ziprasidone IM treatment, and to determine whether this early effect is distinct from a reduction in agitation symptoms...
  11. ncbi request reprint Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data
    Leslie Citrome
    Nathan S Kline Institute for Psychiatric Research and the New York University School of Medicine, Orangeburg, NY 10962, USA
    J Clin Psychiatry 67:638-42. 2006
    ..The objective was to determine the effects of sequential intramuscular/oral ziprasi-done on hostility...
  12. ncbi request reprint The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone
    Peter F Buckley
    Medical College of Georgia, United States
    Schizophr Res 94:99-106. 2007
    ....
  13. ncbi request reprint Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
    David L Dunner
    Center for Anxiety and Depression and the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
    J Clin Psychiatry 68:1071-7. 2007
    ..To evaluate the efficacy and tolerability of adjunctive ziprasidone in subjects with treatment-resistant major depressive disorder (DSM-IV criteria) without psychotic features...